PRO 140 in Treatment-Experienced HIV-1 Subjects
Public ClinicalTrials.gov record NCT03902522. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Two-Part, Single-Arm, Open Label, 25-Week Trial With PRO 140 in Treatment-Experienced HIV-1 Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of the trial are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with failing ART (antiretroviral therapy) during the initial one-week treatment period, and in combination with Optimized Background Therapy during the subsequent 24-week treatment period.
Study identification
- NCT ID
- NCT03902522
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 6 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 24, 2018
- Primary completion
- May 17, 2020
- Completion
- May 17, 2020
- Last update posted
- Sep 15, 2025
2018 – 2020
United States locations
- U.S. sites
- 17
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CD02_OpenLabel Investigational Site | Palm Springs | California | 92262 | — |
| CD02_OpenLabel Investigational Site | San Francisco | California | 94115 | — |
| CD02_OpenLabel Investigational Site | New Haven | Connecticut | 06510 | — |
| CD02_OpenLabel Investigational Site | Ft. Pierce | Florida | 34982 | — |
| CD02_OpenLabel Investigational Site | Miami | Florida | 33136 | — |
| CD02_OpenLabel Investigational Site | Miami | Florida | 33139 | — |
| CD02_OpenLabel Investigational Site | Miami | Florida | 33169 | — |
| CD02_OpenLabel Investigational Site | Orlando | Florida | 32803 | — |
| CD02_OpenLabel Investigational Site | West Palm Beach | Florida | 33401 | — |
| CD02_OpenLabel Investigational Site | Decatur | Georgia | 30033 | — |
| CD02_OpenLabel Investigational Site | Chicago | Illinois | 60613 | — |
| CD02_OpenLabel Investigational Site | Wichita | Kansas | 67214 | — |
| CD02_OpenLabel Investigational Site | Syracuse | New York | 13210 | — |
| CD02_OpenLabel Investigational Site | Bellaire | Texas | 77301 | — |
| CD02_OpenLabel Investigational Site | Houston | Texas | 77004 | — |
| CD02_OpenLabel Investigational Site | Houston | Texas | 77098 | — |
| CD02_OpenLabel Investigational Site | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03902522, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 15, 2025 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03902522 live on ClinicalTrials.gov.